UNSPSC 51144112: Chlorphentermine

This classification denotes a cns stimulant with the molecular formula C10H14ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) NHW07912O7, chemically known as 4-chloro-.alpha.,.alpha.-dimethylphenethylamine hydrochloride but more generally known as chlorphentermine, which bears US NIH Compound Identifier 10007. European Medicines Agency schedules Chlorphentermine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06205MIG.

UNSPSC 51144112 Chlorphentermine is a Commodity code that in recent state and local practice encompasses a broader range of pharmaceutical procurement activity than its narrow product name suggests. Recent opportunities posted under this code reflect state and local agencies buying naloxone and drug deactivation systems for community health, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing networks, and exploring direct-to-manufacturer prescription fulfillment models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, covering Minnesota and Oregon). The work spans procurement of finished pharmaceuticals, medical supplies, and related logistics and fulfillment capabilities rather than active pharmaceutical ingredient manufacturing or bulk chemical sourcing.

Recent activity concentrates in Florida and Texas, with multistate procurement through MMCAP spanning the Upper Midwest and Pacific Northwest. Seminole County posted an IFB on June 30, 2026 (due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring vendors to include shipping costs and comply with E-Verify and drug-free workplace certifications. The Texas HHS Commission issued a Request for Information on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to explore direct contracting between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and wholesaler channels. MMCAP issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with product availability required by May 15, 2026 and contract effectiveness July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 10 percent on fixed pricing for the contract term.